GLOBE Joins with ACTFL to Promote Content-Based Language Study around the World

Foreign Language Annals | July 1, 2005| | Copyright

GLOBE is a cooperative effort of schools, led in the United States by a Federal interagency program supported by NASA, NSF, and the U.S. State Department, in partnership with colleges and universities, state and local school systems, and nongovernment organizations. Internationally, GLOBE is a partnership between the United States and over 100 other countries. Over a million primary and secondary students in more than 15,000 schools have taken part in the program; there are more than 28,000 GLOBE-trained teachers and those numbers are growing. The program naturally provides authentic content ...

Read all of this article with a FREE trial to HighBeam Research

Related newspaper, magazine, and trade journal articles from HighBeam Research

(Including press releases, facts, information, and biographies)

Isis Acquires Symphony GenIsis.
PR Newswire ; ISIS 301012 now under Isis' ownership in preparation for partnering CARLSBAD, Calif., Sept. 27 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. , today announced its purchase of all of the...
ISIS PHARMACEUTICALS ANNOUNCES AGREEMENT WITH ZENECA LTD. FOR MANUFACTURE OF NOVEL ANTI-HIV COMPOUND
PR Newswire ; CARLSBAD, Calif., Nov. 16 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIP) announced...Biochemicals (CRB) business, for the manufacture of Isis' anti-HIV compound, ISIS 5320, a phosphorothioate oligonucleotide, eight...
ISIS BEGINS PHASE III CLINICAL TRIALS OF ANTISENSE COMPOUND TO TREAT CMV RETINITIS IN PATIENTS WITH AIDS
PR Newswire ; ...Calif., Dec. 14 /PRNewswire/ -- Isis Pharmaceuticals (Nasdaq: ISIP) announced...controlled, Phase III clinical trials of ISIS 2922, an antisense compound to treat cytomegalovirus...and leads to blindness if not treated. ISIS 2922 is an antisense compound that inhibits...
ISIS 301012 Does Not Interact With Currently Marketed Lipid Lowering Drugs.
PR Newswire ; ...March 13 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. today announced additional data from clinical studies of ISIS 301012 that continue to broaden the potential...In a drug-drug interaction study, ISIS 301012 did not interact with simvastatin...
Isis to Proceed With Development of ISIS 3521 and ISIS 5132 as Novartis Concludes Participation.
PR Newswire ; CARLSBAD, Calif., Nov. 22 /PRNewswire/ -- Isis Pharmaceuticals (Nasdaq: ISIP) announced today that...will conclude its participation in the development of ISIS 3521 and ISIS 5132, two anticancer compounds, at the completion of...
ISIS 301012 Reduces Atherosclerotic Plaques in Animal Models.
PR Newswire ; Data Confirms That ISIS 301012 Has Potential to Benefit Patients With...April 27 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. today announced results of a study showing that ISIS 301012 reduced atherosclerotic plaques, apoB...
Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes.
PR Newswire ; ...Oct. 18 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. today announced...SGLT2) to its development pipeline. ISIS 388626, a generation 2.2 antisense drug...increase glucose excretion, complements Isis' existing pipeline of drugs in development...
Isis Begins Phase I/II Trial of Second Generation CMV Retinitis Compound
PR Newswire ; ...Calif., Jan. 6 /PRNewswire/ -- Isis Pharmaceuticals (Nasdaq: ISIP) announced...beginning of Phase I/II clinical trials of ISIS 13312, a compound to treat cytomegalovirus...threatening infection in patients with AIDS. ISIS 13312 is the company's first compound...
Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568.
PR Newswire ; ISIS 325568 is an Antisense Drug Targeting Glucagon...Oct. 2 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced today it...initializing the Phase 1 clinical trial of ISIS 325568. The collaboration between Isis and...
Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline.
PR Newswire ; ISIS-FXIRx to Treat Clotting Disorders ISIS-SMNRx to Treat Spinal Muscular Atrophy R&D Webcast, December 3rd, 11:30 a.m. EST at www.isispharm.com Isis to Present Additional Details on Both Programs CARLSBAD, Calif...

Find more facts and information related to the article "GLOBE Joins with ACTFL to Promote Content-Based ..."